ResMed (RMD)

• Market cap: $31.5B
• 1 day: 0.17%
• 5 days: 1.26%
• 1 month: -3.80%
• 3 months: -13.84%
• 6 months: -9.67%
• Year to date: -6.14%
• 1 year: 16.40%
• 5 years: 35.10%
• 10 years: 192.23%
• Sector: Healthcare
• Industry: Medical Instruments & Supplies

About: ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Employees: 9,980

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

119% more first-time investments, than exits

New positions opened: 147 | Existing positions closed: 67

28% more repeat investments, than reductions

Existing positions increased: 329 | Existing positions reduced: 257

8% more funds holding

Funds holding: 786 [Q3] → 851 (+65) [Q4]

2.55% more ownership

Funds ownership: 58.71% [Q3] → 61.26% (+2.55%) [Q4]

2% less capital invested

Capital invested by funds: $21B [Q3] → $20.6B (-$458M) [Q4]

30% less funds holding in top 10

Funds holding in top 10: 10 [Q3] → 7 (-3) [Q4]

79% less call options, than puts

Call options by funds: $86.1M | Put options by funds: $416M

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $240 12% upside
• Avg. target: $267 25% upside
• High target: $286 33% upside

5 analyst ratings

• positive: 3 60%
• neutral: 2 40%
• negative: 0 0%

Keybanc Tim Rezvan 45% 1-year accuracy 20 / 44 met price target	25% upside $269	Overweight Maintained	21 Apr 2025
Stifel Jonathan Block 5% 1-year accuracy 1 / 20 met price target	12% upside $240	Hold Maintained	5 Mar 2025
JP Morgan David Low 0% 1-year accuracy 0 / 1 met price target	33% upside $286	Overweight Maintained	31 Jan 2025
Keybanc Brett Fishbin 13% 1-year accuracy 2 / 16 met price target	31% upside $280	Overweight Maintained	31 Jan 2025
Piper Sandler Adam Maeder 33% 1-year accuracy 4 / 12 met price target	21% upside $260	Neutral Maintained	31 Jan 2025